Galecto
IPORedefining care for people with blood disorders
Public · Copenhagen, Denmark · Founded 2010 · $446.9M raised
- Headquarters
- Copenhagen
- Employees
- 11–50
- Founded
- 2010
- Business Model
- B2B
- Website
- galecto.com
- Total Funding
- $446.9M
- Last Round
- $285.0M Series CNov 2025
- Rounds
- 4
- Type
- Public
About
Galecto is a clinical-stage biopharmaceutical company developing small-molecule and antibody therapeutics targeting galectin proteins for the treatment of fibrosis, cancer, and hematologic disorders. Its pipeline includes programs for idiopathic pulmonary fibrosis and myeloproliferative neoplasms. In March 2026 the company announced a name change to Damora Therapeutics following its acquisition of Damora Therapeutics and a strategic pivot to mutant calreticulin-driven blood disorders.
Summary
Galecto is a Biotech company based in Copenhagen, Denmark, founded in 2010. It has raised $446.9M in total across 4 rounds, most recently a $285.0M Series C round in Nov 2025. Investors include Soleus Capital, Ysios Capital and OrbiMed.
Tech & App Stack
1 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Nov 2025
Sign up to see all 5 rounds
Pre-Seed through Series C — per-round amounts, valuations, and who invested in each round.
Investors
Soleus Capital
1 round
Ysios Capital
1 round
OrbiMed
1 round
Novo Nordisk Foundation
1 round
EIR Ventures
1 round
Cormorant Asset Management
1 round
Janus Fund
1 round
HBM Healthcare Investments
1 round
Bristol Myers Squibb
1 round
Maverick Ventures
1 round
Seventure Partners
1 round
Novo Holdings A/S
1 round
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/galecto"><img src="https://indexed.vc/api/badge/company/galecto" alt="Galecto on Indexed.vc" width="260" height="76" /></a>